ARCHIVES

Boyd Steps Down As DTP Director, Returns to Research

This article is from The Cancer Letter archive.

Vol. 16 No. 07 | February 16, 1990

Download PDF Visit The Full Archive

Related Articles

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013

How Much Is Life Worth? The $440 Billion Question

July 31, 2009

Letter: A Modest Proposal To Abolish FDA

January 26, 1996

For Frederick, Unseat Program Resources Inc.

March 3, 1995

NCI Offers Chlorozotocin

November 18, 1977

FDA Advisors: DepoCyt May Test Accelerated Approval Mechanism

November 27, 1998